DDInter461 DDInter596
Cytarabine can cause developmental toxicity according to an independent committee of scientific and health experts.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Cytarabine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Cytarabine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Cytarabine {u} (Compound) upregulates {v} (Gene) E2F2
E2F2 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Cytarabine {u} (Compound) downregulates {v} (Gene) CCNA2
CCNA2 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Cytarabine {u} (Compound) upregulates {v} (Gene) RGS2
RGS2 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Cytarabine {u} (Compound) binds {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Cytarabine {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Cytarabine {u} (Compound) binds {v} (Gene) ABCC10
ABCC10 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Doxorubicin (Compound)
Cytarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Doxorubicin (Compound)
Cytarabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxorubicin (Compound)
Cytarabine (Compound) upregulates E2F2 (Gene) and E2F2 (Gene) is upregulated by Doxorubicin (Compound)
Cytarabine (Compound) downregulates CCNA2 (Gene) and CCNA2 (Gene) is downregulated by Doxorubicin (Compound)
Cytarabine (Compound) upregulates RGS2 (Gene) and RGS2 (Gene) is downregulated by Doxorubicin (Compound)
Cytarabine (Compound) binds DCK (Gene) and DCK (Gene) is downregulated by Doxorubicin (Compound)
Cytarabine (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Doxorubicin (Compound) and TOP2A (Gene) is downregulated by Doxorubicin (Compound)
Cytarabine (Compound) binds ABCC10 (Gene) and ABCC10 (Gene) is bound by Doxorubicin (Compound) and ABCC10 (Gene) is upregulated by Doxorubicin (Compound)